Search Within

Genitourinary Oncology Service

  1. "Martin Voss"
Formats
  1. Meeting Abstract (154)
  2. Journal Article (124)
  3. Review (6)
  4. Editorial (5)
  5. Guidelines (2)
  6. Research Letter (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (294)
  2. Solid Tumor Oncology Division (294)
  3. Hematology-Oncology Fellows (111)
  4. Weinberg Fellows (108)
  5. Human Oncology and Pathogenesis Program (106)
  6. Surgery (106)

More Groups

People
  1. Martin Voss (294)
  2. Robert Motzer (178)
  3. Abraham Hakimi (97)
  4. Darren Feldman (81)
  5. Chung-Han Lee (75)
  6. Maria Carlo (68)

More People

Years
  1. 2025 (12)
  2. 2024 (15)
  3. 2023 (21)
  4. 2022 (24)
  5. 2021 (30)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (120)
  2. Clinical Cancer Research (18)
  3. BJU International (15)
  4. Annals of Oncology (13)
  5. Journal for ImmunoTherapy of Cancer (12)
  6. Clinical Genitourinary Cancer (8)

More Publications

Publishers
  1. American Society of Clinical Oncology (124)
  2. American Association for Cancer Research (26)
  3. Wiley Blackwell (22)
  4. Elsevier Inc. (21)
  5. Oxford University Press (19)
  6. Biomed Central Ltd (15)

More Publishers

Results (294)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line pembrolizumab plus lenvatinib for advanced non–clear-cell renal cell carcinoma: Updated results from the phase 2 KEYNOTE-B61 trial
    Journal Article

    Voss, M. H.; Gurney, H.; Atduev, V.; Suarez, C.; Climent, M. A.; Pook, D.; Tomczak, P.; Barthélémy, P.; Lee, J. L.; Nalbandian, T.; more...
    European Urology (2025)

    Fulltext@MSK | Save
  • Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma
    Journal Article

    Beckermann, K. E.; Shah, N. J.; Campbell, M. T.; Haas, N. B.; Nelson, A.; Ornstein, M. C.; Mao, S.; Keshava-Prasad, H. S.; Hammers, H.; Gao, X.; more...
    The Oncologist (2025)

    Fulltext@MSK | Save
  • Patient-reported experience with an immunotherapy telehealth platform
    Meeting Abstract

    Daly, R. M.; Malling, C.; Dagostino, A.; Bange, E. M.; Preeshagul, I. R.; Aggen, D. H.; Carlo, M.; Chen, M. F.; Eng, J.; Ng, K. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Effect of post-discharge symptom monitoring on hospital readmissions: A randomized trial
    Meeting Abstract

    Daly, R. M.; Mao, J. J.; Cracchiolo, J. R.; Holland, J. C.; Huang, J.; Ebstein, A. M.; Walters, C.; Ackerman, J.; Raj, N. P.; Sanford, R. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • KEAP1 mutated renal cell carcinoma (RCC): Characterization of an emerging molecularly defined RCC subtype
    Meeting Abstract

    Carlo, M.; Chen, Y. B.; Knezevic, A.; Zong, G.; Bakouny, Z.; Kemel, Y.; Latham, A.; Liu, Y. L.; Shah, N. J.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clear and non-clear cell renal cell carcinomas and the ability to engage in oxidative phosphorylation
    Meeting Abstract

    Bakouny, Z.; Boscenco, S.; Cui, R.; Ryu, K.; Kotecha, R. R.; Carlo, M.; Voss, M. H.; Hakimi, A. A.; Motzer, R. J.; Gammage, P. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
    Journal Article

    Gouda, M. A.; Voss, M. H.; Tawbi, H.; Gordon, M.; Tykodi, S. S.; Lam, E. T.; Vaishampayan, U.; Tannir, N. M.; Chaves, J.; Nikolinakos, P.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Outcomes with first-line ipilimumab and nivolumab for patients with metastatic renal cell carcinoma by number of doses
    Meeting Abstract

    Doshi, S. D.; Sanmiguel, A. L.; Knezevic, A.; Kotecha, R. R.; Shah, N. J.; Carlo, M.; Feldman, D. R.; Motzer, R. J.; Voss, M. H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study
    Meeting Abstract

    Dizman, N.; Doshi, S. D.; Knezevic, A.; Feinaj, A.; Sayegh, N.; Hobeika, C.; Alaghehbandan, R.; Rives, H.; Zengin, Z. B.; Braun, D. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save